A Phase II Trial to Correlate Early Clinical Response to Pathologic Outcome With Neoadjuvant Systemic Therapy in Patients With Early Stage Breast Cancer
Latest Information Update: 18 Jan 2024
At a glance
- Drugs Carboplatin (Primary) ; Cyclophosphamide (Primary) ; Doxorubicin (Primary) ; Paclitaxel (Primary) ; Pembrolizumab (Primary) ; Pertuzumab (Primary) ; Pertuzumab/trastuzumab (Primary) ; Trastuzumab (Primary)
- Indications Early breast cancer; HER2 positive breast cancer; Male breast cancer
- Focus Therapeutic Use
- Acronyms RESPONSE
- 14 Jun 2023 Planned End Date changed from 1 Sep 2029 to 1 Nov 2029.
- 14 Jun 2023 Planned primary completion date changed from 15 Jun 2027 to 1 Aug 2027.
- 14 Jun 2023 Status changed from not yet recruiting to recruiting.